Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.72 USD | +0.56% | +24.58% | +21.45% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 82% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company has a low valuation given the cash flows generated by its activity.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.93 times its estimated earnings per share for the ongoing year.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+21.45% | 8.74B | D+ | ||
-4.84% | 182B | C+ | ||
+0.56% | 110B | C | ||
-3.35% | 68.11B | A | ||
+2.39% | 50.53B | B- | ||
+9.36% | 44.8B | B- | ||
+2.70% | 40.7B | B+ | ||
+24.51% | 32.3B | B | ||
+3.43% | 26.53B | A- | ||
-0.32% | 24.96B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GMED Stock
- Ratings Globus Medical, Inc.